Abstract 310: Immunophenotyping tumors by novel multiplex immunofluorescence and AQUA (Automated Quantitative Analyses) algorithms to guide development of immunotherapies
Ju Young Kim(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Deborah Knee, Alexander Savchenko(Precision for Medicine (United States)), John A. H. Hoerter(Genomics Institute of the Novartis Research Foundation), Robbin Newlin(Genomics Institute of the Novartis Research Foundation), James Santos, Patrizia Barzaghi-Rinaudo(Novartis (Switzerland)), Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Brian Schwartz, Valerie Tolley(Genomics Institute of the Novartis Research Foundation), John W. Fathman(Genomics Institute of the Novartis Research Foundation), Justin Santos, Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Karyn Colman(Genomics Institute of the Novartis Research Foundation), Lori A. Iaconis, Emmanuel Pacia, Nathan Roscoe(Navidea Biopharmaceuticals (United States)), Minhua Qiu(Genomics Institute of the Novartis Research Foundation), Xun� Li(Beijing University of Chinese Medicine), Jacob Levy(Navidea Biopharmaceuticals (United States)), T A Carolan(Genomics Institute of the Novartis Research Foundation), Steven L. Bender(Genomics Institute of the Novartis Research Foundation), Andy Schumacher(Genomics Institute of the Novartis Research Foundation), Margaret E. McLaughlin(Novartis (Switzerland)), Thai H. Tran(Navidea Biopharmaceuticals (United States))
Cited by 0
Related Papers
Restoration of p53 function leads to tumour regression in vivo
|Nature|2007|1.8k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Antibody validation
|BioTechniques|2010|601